Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

A. R. Jazieh, R. Komrokji, A. Gupta, S. Patil, D. Flora, M. Knapp, M. Issa, Nagla Fawzy Miligy Abdel Karim

Research output: Contribution to journalArticle

9 Scopus citations


This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000mg/m2 day 1 & 8 and Irinotecan 100 mg/m 2 day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10) experienced partial response and 14 (70) experienced stable disease. The median time to disease progression was 4 months (95 CI: 2.86.6). The 1 year and 2 year survival rates were 36 and 27, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

Original languageEnglish (US)
Pages (from-to)932-936
Number of pages5
JournalCancer Investigation
Issue number9
StatePublished - Oct 22 2009
Externally publishedYes



  • Angiogenesis inhibitor
  • Chemotherapy
  • Thalidomide, non small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this